Personal Finance

Why This Healthcare ETF Was Last Week's Biggest Winner

IHE Price Chart
IHE Price Chart

IHE Price data by YCharts

So what was the secret to IHE's success this week? Let's take a closer look at the inner workings of this fund to see if we can figure out an answer.

iShares Dow Jones US Pharmaceuticals ETF key statistics

Inception Year 2006
Number of Holdings 42
Net Assets $644 million
Average P/E Ratio 30
Yield 1.07%
Expense Ratio 0.45%


The goal of IHE is to give investors an easy way to buy a diversified portfolio of stocks from the U.S. pharmaceutical sector. Right now it holds a stake in 42 companies, with the bulk of its assets concentrated in its top holdings.

Top 10 positions

Company Symbol % Assets
Johnson & Johnson JNJ 9.53%
Pfizer PFE 8.73%
Merck & Co. MRK 7.48%
Bristol-Myers Squibb BMY 6.93%
Eli Lilly LLY 5.48%
Allergan AGN 5.39%
Zoetis ZTS 3.91%
Mylan NV MYL 3.21%
Jazz Pharmaceuticals JAZZ 2.96%
Anacor Pharmacetuicals ANAC 2.67%


Add them up, and these 10 stocks comprise more than 52% of the fund's total assets, so when a few of these stocks perform well -- as they did this week -- the the whole fund does, too.

What went right this week?

Most of this fund's top holdings ended the trading week higher, but two companies in particular -- Mylan NV (NASDAQ: MYL) and Allergan PLC (NYSE: AGN) -- put up standout performances.

AGN Price data by YCharts

Allergan's stock has been getting a lot of attention from billionaire investors, causing shares to soar this week. Recent filings with the SEC showed that John Paulson, one of the world's wealthiest hedge fund managers, made Allergan into his fund's biggest position, comprising about 10.8% of its portfolio. Other billionaire investors, such as Third Point's Dan Loeb and Elliot Management's Paul Singer, have also put a substantial portion of their fund's assets into Allergan.

But the reason the stock jumped this week is that billionaire investor Carl Icahn disclosed that he, too, has taken a big position in the Botox maker. Icahn has a track record of taking big stock positions and then agitating for shareholder-friendly changes, causing many investors to religiously follow his moves.

Mylan NV's stock leapt this week after news broke that its biosimilar version of Roche Holding AG 's breast-cancer drug Herceptin performed just as well in phase 3 trials as the brand-name drug. That's great news, since Herceptin sales each yet exceed $6 billion, giving Mylan a real chance at stealing some market share in the not too distant future if regulators give it the thumbs-up.

What's next for IHE?

IHE has now claimed the title of the week's best-performing healthcare ETF for the fourth time this year, which speaks volumes about how well its strategy of investing in the pharma giants works. With a low expense ratio and a history of winning, this ETF seems like a great choice for investors who want more exposure to the healthcare space.

A secret billion-dollar stock opportunity

The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Personal Finance Videos

    The Motley Fool

    Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

    Learn More